Report from the 163rd annual meeting of the American Psychiatric Association, New Orleans LA, May 22-26, 2010 – Neuroleptic malignant syndrome is currently defined as severe muscle rigidity and elevated temperature associated with the use of neuroleptic medication, and includes >2 of the following features: diaphoresis, dysphagia, tremor, incontinence, changes in level of consciousness ranging from confusion to coma, mutism, tachycardia, elevated/labile blood pressure, leucocytosis and laboratory evidence of muscle injury (APA. DSM-IV TR, Washington DC, 2000).